Trial Profile
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary) ; Azacitidine; Azacitidine; Cytarabine; Decitabine
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASTRAL-1
- Sponsors Astex Pharmaceuticals; Otsuka Pharmaceutical
- 08 Dec 2020 Results of a subgroup analysis presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.